Joo Yong Lee1, Ho Won Kang2, Koon Ho Rha1, Nam Hoon Cho3, Young Deuk Choi1, Sung Joon Hong1, Kang Su Cho4. 1. Department of Urology, Severance Hospital, Urological Science Institute, Yonsei University College of Medicine, Seoul, Korea. 2. Department of Urology, Chungbuk National University College of Medicine, Cheongju, Korea. 3. Department of Pathology, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea. 4. Department of Urology, Gangnam Severance Hospital, Urological Science Institute, Yonsei University College of Medicine, 211 Eonju-ro, Gangnam-gu, Seoul, 06273, Korea. kscho99@yuhs.ac.
Abstract
PURPOSE: We investigated the long-term prognostic impact of age-adjusted Charlson comorbidity index (ACCI) on overall mortality (OM), cancer-specific mortality (CSM), and other-cause mortality (OCM) according to risk stratification in patients with prostate cancer who underwent radical prostatectomy. METHODS: Data from 542 patients who underwent radical prostatectomy between 1992 and 2006 were analyzed. The impact of preoperative variables including age, prostate-specific antigen, biopsy Gleason sum, clinical stage, and ACCI on OM, CSM, and OCM were analyzed according to risk groups, with a median follow-up of 101 months. RESULTS: Subjects were stratified into either the high-risk group (n = 241) or the non-high-risk group (n = 301). Cox proportional hazards model demonstrated that the ACCI was the only significant predictor for OM in all patients (hazard ratio, HR 1.41; 95 % confidence interval, CI 1.19-1.66), non-high-risk group (HR 1.45; 95 % CI 1.09-1.91), and high-risk group (HR 1.37; 95 % CI 1.11-1.69). In competing risk analysis, CSM was not associated with the ACCI in either risk group. However, the ACCI had a significant impact on OCM in both the non-high-risk (HR 1.55; 95 % CI 1.16-2.1) and high-risk groups (HR 1.60; 95 % CI 1.23-2.08). A Bayesian model averaging approach verified that the ACCI was the most powerful predictor for OM and OCM in the both high-risk and non-high-risk groups. CONCLUSIONS: A thorough assessment of comorbidities is mandatory in establishing prognoses, even when considering invasive treatment modalities in high-risk prostate cancer patients.
PURPOSE: We investigated the long-term prognostic impact of age-adjusted Charlson comorbidity index (ACCI) on overall mortality (OM), cancer-specific mortality (CSM), and other-cause mortality (OCM) according to risk stratification in patients with prostate cancer who underwent radical prostatectomy. METHODS: Data from 542 patients who underwent radical prostatectomy between 1992 and 2006 were analyzed. The impact of preoperative variables including age, prostate-specific antigen, biopsy Gleason sum, clinical stage, and ACCI on OM, CSM, and OCM were analyzed according to risk groups, with a median follow-up of 101 months. RESULTS: Subjects were stratified into either the high-risk group (n = 241) or the non-high-risk group (n = 301). Cox proportional hazards model demonstrated that the ACCI was the only significant predictor for OM in all patients (hazard ratio, HR 1.41; 95 % confidence interval, CI 1.19-1.66), non-high-risk group (HR 1.45; 95 % CI 1.09-1.91), and high-risk group (HR 1.37; 95 % CI 1.11-1.69). In competing risk analysis, CSM was not associated with the ACCI in either risk group. However, the ACCI had a significant impact on OCM in both the non-high-risk (HR 1.55; 95 % CI 1.16-2.1) and high-risk groups (HR 1.60; 95 % CI 1.23-2.08). A Bayesian model averaging approach verified that the ACCI was the most powerful predictor for OM and OCM in the both high-risk and non-high-risk groups. CONCLUSIONS: A thorough assessment of comorbidities is mandatory in establishing prognoses, even when considering invasive treatment modalities in high-risk prostate cancerpatients.
Authors: Ian Thompson; James Brantley Thrasher; Gunnar Aus; Arthur L Burnett; Edith D Canby-Hagino; Michael S Cookson; Anthony V D'Amico; Roger R Dmochowski; David T Eton; Jeffrey D Forman; S Larry Goldenberg; Javier Hernandez; Celestia S Higano; Stephen R Kraus; Judd W Moul; Catherine M Tangen Journal: J Urol Date: 2007-06 Impact factor: 7.450
Authors: Stephen A Boorjian; R Jeffrey Karnes; Rosalia Viterbo; Laureano J Rangel; Eric J Bergstralh; Eric M Horwitz; Michael L Blute; Mark K Buyyounouski Journal: Cancer Date: 2011-01-10 Impact factor: 6.860
Authors: Kenneth Westover; Ming-Hui Chen; Judd Moul; Cary Robertson; Thomas Polascik; Daniel Dosoretz; Michael Katin; Sharon Salenius; Anthony V D'Amico Journal: BJU Int Date: 2012-04-30 Impact factor: 5.588
Authors: Michael J Zelefsky; James A Eastham; Angel M Cronin; Zvi Fuks; Zhigang Zhang; Yoshiya Yamada; Andrew Vickers; Peter T Scardino Journal: J Clin Oncol Date: 2010-02-16 Impact factor: 44.544
Authors: Tomás Merino; Ignacio F San Francisco; Pablo A Rojas; Piero Bettoli; Alvaro Zúñiga; Pelayo Besa Journal: BMC Cancer Date: 2013-11-08 Impact factor: 4.430
Authors: In Kyong Kim; Joo Yong Lee; Jong Kyou Kwon; Jae Joon Park; Kang Su Cho; Won Sik Ham; Sung Joon Hong; Seung Choul Yang; Young Deuk Choi Journal: Korean J Urol Date: 2014-09-05
Authors: Jae Won Park; Dong Hoon Koh; Won Sik Jang; Joo Yong Lee; Kang Su Cho; Won Sik Ham; Koon Ho Rha; Woo Hee Jung; Sung Joon Hong; Young Deuk Choi Journal: PLoS One Date: 2018-06-20 Impact factor: 3.240